The alfapump system has been proposed as a new treatment for the management of refractory ascites. The system removes ascites from the peritoneal cavity to urinary bladder, producing a continuous low-volume paracentesis. The aim of the study is to investigate the effects of treatment with the alfapump TM system on kidney and circulatory function in patients with cirrhosis and refractory ascites. This was a prospective study including 10 patients with cirrhosis and refractory ascites. Primary outcomes were changes in glomerular filtration rate (GFR), as assessed by isotopic techniques, and changes in circulatory function assessed by arterial pressure, cardiac output, and activity of vasoconstrictor systems. Secondary outcomes were the need for large-volume paracentesis and adverse events. Follow-up was 1 year. GFR decreased significantly from 67 mL/ minute/1.73 m 2 (41-90 mL/minute/1.73 m 2 ) at baseline to 45 mL/minute/1.73 m 2 (36-74 mL/minute/1.73 m 2 ) at month 6 (P 5 0.04). Mean arterial pressure and cardiac output did not change significantly; however, there was a marked increase in plasma renin activity and norepinephrine concentration (median percent increase with respect to baseline 1191% and 59%, respectively). There were 68 episodes of complications of cirrhosis in 8 patients during follow-up, the most frequent being acute kidney injury. In conclusion, treatment with alfapump TM system was associated with marked activation of endogenous vasoconstrictor systems and impairment of kidney function. The chronological relationship observed between kidney impairment and vasoconstrictor systems activation after device insertion suggests a cause-effect relationship, raising the possibility that treatment with alfapump impairs effective arterial blood volume mimicking a postparacentesis circulatory dysfunction syndrome. In this context, the potential role of albumin in counteracting these effects should be investigated in future studies.
dysfunction is characterized by splanchnic arterial vasodilation leading to a reduction in effective arterial blood volume and activation of endogenous vasoconstrictor systems, particularly the renin-angiotensinaldosterone system and the sympathetic nervous system, in order to maintain arterial pressure within normal limits. The increased activity of these systems has a positive effect because they help maintain arterial pressure within normal levels, but they have deleterious effects in the kidney, particularly sodium retention leading to ascites formation, and renal vasoconstriction with impairment of kidney function and development of acute kidney injury (AKI) in some cases. (2) Management of ascites is based on a low-sodium diet and diuretic treatment. (4, 5) However, approximately 10% of patients with cirrhosis and ascites will develop refractory ascites during follow-up. The first-line treatment for patients with refractory ascites is large-volume paracentesis (LVP). (4, 5) In those patients in whom more than 5 L are removed, the concomitant administration of intravenous albumin is mandatory to prevent postparacentesis circulatory dysfunction (PPCD) syndrome. This syndrome is characterized by a reduction of effective arterial blood volume and a marked activation of endogenous vasoconstrictor systems, particularly the renin-angiotensin-aldosterone system. (5, 6) The occurrence of PPCD is associated with a poor prognosis, characterized by rapid reaccumulation of ascites, high risk of hepatorenal syndrome and hyponatremia, and increased mortality. (5) LVP with albumin administration is a safe procedure with a low rate of adverse events, and it is generally performed in a day hospital setting. However, the requirement of repeated LVP leads to an increased number of hospital visits, which may impair health-related quality of life. Transjugular intrahepatic portosystemic shunt (TIPS) represents an alternative treatment to repeated LVP and albumin for patients with refractory ascites. (4, 5, 7, 8) Nevertheless, it should be considered that TIPS is not recommended in patients with advanced liver failure and that the insertion of TIPS is associated with a high rate of hepatic encephalopathy, which develops in approximately 30%-50% of patients. (7, 8) Therefore, TIPS remains as an alternative therapy only for selected patients. (4, 5) Considering these limited treatment options for patients with refractory ascites, recently a new treatment approach was designed: the automated low-flow ascites pump system (alfapump TM , Sequana Medical AG, Zurich, Switzerland). (9) The alfapump system is a subcutaneously implanted, battery-powered device that moves ascites from the peritoneal cavity into the urinary bladder where it is eliminated through normal urination. The system has internal sensors that monitor the pressure in the peritoneal cavity and the bladder in order to stop pump operation if there is no ascites in the peritoneal cavity or if there is excessive bladder distension because the bladder becomes full. The operation of the pump is programmed by a wireless system. The total amount of ascitic fluid to be removed daily is individualized according to the patient's requirements. The alfapump system is activated every 10-15 minutes and moves 3-30 mL of ascites into the bladder in each cycle. The system is inactive during the night to ensure that the patient can rest at night. The only patient interaction with the system is the need to daily recharge the battery, with a wireless charger through the skin (20 minutes/day). (9) A potential issue of the alfapump system is whether the continuous elimination of ascites without concomitant administration of albumin may cause circulatory and/or kidney dysfunction by causing an impairment of the effective arterial blood volume. This information is important if the alfapump system is to become an alternative to LVP and TIPS for refractory ascites. So far, the published information on the alfapump system is very limited, and no study has specifically performed a careful evaluation of kidney and circulatory function using state-of-the-art analytical techniques in patients treated with this system. Therefore, the aim of the current study was to investigate the effect of the alfapump system on kidney and circulatory function in patients with cirrhosis and refractory ascites.
Patients and Methods

STUDY DESIGN
This was a prospective, proof-of-concept, single-group study that included 10 patients with cirrhosis and refractory ascites seen at the Liver Unit of Hospital Cl ınic in Barcelona from November 2011 to June 2013. Patients were eligible if they were 18 years old and had cirrhosis defined by standard criteria associated with refractory ascites defined by accepted diagnostic criteria from the International Club of Ascites, (5) with a requirement of 2 LVP during 3 months prior to study inclusion. Exclusion criteria were as follows:
1. Bacterial infections or gastrointestinal bleeding during the last 7 days. 2. Serum creatinine 2 mg/dL. 3. Serum bilirubin > 5 mg/dL. 4. Severe coagulopathy defined as platelet count <40,000 or prothrombin time <40%. 5. Recurrent spontaneous bacterial peritonitis or urinary tract infections defined as 2 episodes during the last 6 months. 6. Evidence of loculated ascites. 7. Hepatocellular carcinoma exceeding Milan criteria. 8. Previous liver transplant. 9. Obstructive uropathy or bladder abnormalities that could contraindicate the implantation procedure.
All patients signed a written informed consent document and gave permission for blood and urine samples to be used in the study following current national and institutional guidelines for sample storage and usage for research purposes. The study was approved by the institutional review board of our center. The study was designed by the authors and sponsored by Sequana Medical, the producer of the alfapump system, which also provided the devices used in the patients free of charge. The study was registered in clinicaltrials.gov (NCT01438970).
The primary end point of the study was to investigate the effect of treatment with the alfapump system on kidney and circulatory function. Kidney function was assessed by changes in glomerular filtration rate (GFR), measured by state-of-the-art isotopic technique using chromium-51 labeled ethylenediamine tetraacetic acid ( 51 Cr-EDTA) at baseline, day 7, and months 1 and 6.
(10) Circulatory function was assessed by mean arterial pressure measured at each study visit; cardiac output estimated by echocardiography measured at baseline, day 7, and month 1; and activity of the renin-angiotensin system, sympathetic nervous system, and vasopressin measured at baseline; days 2, 7, and 14; and months 1 and 6. Secondary end points included the following: The study follow-up period was 12 months after alfapump implantation.
ANALYTICAL METHODS
GFR was measured by 51
Cr-EDTA isotopic technique (see Supporting Information). Plasma renin activity (PRA), aldosterone, norepinephrine, and vasopressin were measured using previously described methods. (11) Interleukin 6 (IL6) and tumor necrosis factor a (TNFa) were measured using a commercial enzyme-linked immunosorbent assay kit (Diasource; Louvain-laNeuve, Belgium).
Alfapump Implantation Procedure
A LVP associated with albumin infusion (8 g per L of ascites removed) was performed in all patients the day before implantation of the pump. All patients received antibiotic prophylaxis with ceftazidime 2 g plus teicoplanin 400 mg prior to and 8 hours after surgery. Paracetamol was given as painkiller during the first postoperative days if needed. Nonsteroidal antiinflammatory drugs (NSAIDs) were not given because they are nephrotoxic in patients with cirrhosis. (12) 
Management of Patients During the Study
After implantation of the alfapump system, all patients were kept in the hospital for 7 days for close observation and monitoring of kidney and circulatory function. All patients received antibiotic prophylaxis, consistent with that for spontaneous bacterial peritonitis, with norfloxacin 400 mg/day. In order to rule out surgical-related complications and to avoid adverse events, particularly hypovolemia in a patient with a very recent surgical procedure, the device was kept off during the first 24 hours after surgery. If there were no complications, the device was activated on day 2 with a daily ascitic fluid volume extraction of 500 cc/day in all patients, which was maintained until day 7. The initial daily ascitic fluid volume extraction was set at a relatively low volume (500 cc/ day), an amount which is close to the average volume of ascites retained in patients with refractory ascites under a low-sodium diet. Afterward, daily ascitic fluid volume extraction was adjusted individually according to the patient's requirements in order to maintain a stable body weight. Correct operation of the alfapump system and daily volume extraction were assessed at each study visit (daily during the first 7 days; afterward on days 14 and 21 and months 1, 2, 3, 6, 9, and 12). During follow-up, albumin administration was only given if patients required a LVP or in case of spontaneous bacterial peritonitis or development of AKI with serum creatinine of >1.5 mg/dL. No more albumin was given throughout the study.
Diuretic treatment was withdrawn in all patients during the first week after implantation. Afterward, treatment with diuretics was only administered in patients with leg edema. A moderately low-sodium diet was recommended to all patients before discharge and adherence to the diet was self-reported in each study visit. During the study, patients were managed according to current guidelines. (4, 5, 13) Study procedures were performed during a 12-month follow-up period. Afterward, if there were no complications, the alfapump system was maintained and patients were controlled in the outpatient clinic with the standard clinical and analytical follow-up visits for patients with decompensated cirrhosis.
Definitions
AKI was defined as an increase in serum creatinine of 0.3 mg/dL within 48 hours after implant or an increase in serum creatinine of 50% from baseline within 7 days after implant. (14) The baseline serum creatinine used was the serum creatinine value of the day before implantation of the alfapump system. AKI stages were defined according to the Acute Kidney Injury Network criteria. (14) Hyponatremia was defined as a decrease >5 mEq/L in serum sodium concentration with respect to baseline values, to a final value of <130 mEq/L.
Statistical Analysis
Results for continuous variables are expressed as median (interquartile range [IQR] ). Categorical variables are expressed as number and percentage. Comparisons of main variables at different time points during study follow-up were made with 1-way analysis of variance (ANOVA) with repeated measures. All statistical analyses were performed using SPSS, version 20.0 (IBM, Armonk, NY). The significance level for all statistical tests was set at 0.05 for 2-tailed. 
Results
BASELINE CHARACTERISTICS OF PATIENTS
Demographical and clinical data and liver and kidney function tests of patients included in the study are shown in Table 1 . Out of the 10 patients included, 6 patients were male, and most of them had alcoholrelated cirrhosis. Overall patients had moderate impairment of liver and kidney function with median Model for End-Stage Liver Disease (MELD) score of 11 (range, from 7 to 21) and GFR of 67 mL/minute/ 1.73 m 2 . All patients included had been on treatment with LVP for more than 1 year before study inclusion, with a median of 9 LVP during the 3 months prior to the inclusion in the study. Table 2 shows changes in kidney function, hemodynamic parameters, and endogenous vasoconstrictor systems activity during the study period. The most relevant finding was a significant decrease in GFR during follow-up with respect to baseline value (P 5 0.04). Overall, median decrease of GFR at the end of treatment with respect to baseline was -16.5 mL/minute/1.73 m 2 , with a median decrease of -23%. Figure 1 shows individual values of GFR from all patients during study follow-up. These findings indicate that an impairment of kidney function occurred during the study period.
EFFECTS OF ALFAPUMP ON KIDNEY AND CIRCULATORY FUNCTION
There were no significant changes in mean arterial pressure or cardiac output during the study period. By contrast, there was a significant and marked increase in PRA (P 5 0.01) and norepinephrine concentration (P 5 0.01) that started at month 1 and was more marked toward the end of the study period. Median percent increase in PRA and norepinephrine at the end of treatment with respect to baseline was of 1191% and 159%, respectively. Increases in aldosterone and vasopressin were not statistically significant. Figure 2 shows individual values of PRA and norepinephrine throughout the study. Overall, there was a progressive increase of both parameters after day 7 in the majority of patients. These results suggest that a marked decrease in effective arterial blood volume occurred during the study period. Although there was a chronological relationship between decrease in GFR and increase in PRA and norepinephrine concentration, correlations between changes in GFR and changes in hormones were not statistically significant. There were no significant changes in IL6 or TNF-a levels during the study (Table 2) .
FIG. 1.
GFR measured by isotopic techniques during the study follow-up period. This shows individual values of GFR in all patients at baseline and at day 7, month 1, and month 6 after alfapump system implantation. 
EFFECTS OF ALFAPUMP ON MANAGEMENT OF ASCITES
As described above, after the first 7 days with ascitic fluid volume extraction of 500 cc/day in all patients, the amount of ascitic fluid mobilization by the alfapump system was individualized in each patient according to changes in body weight. Median (IQR) daily ascitic fluid volume extraction during the study was 500 (500-500), 700 (500-900), 950 (325-1850), 1000 (600-1700), and 800 (375-1450) mL at day 7 and months 1, 3, 6 and 12, respectively. The highest daily ascitic fluid volume extraction was 2000 mL and the lowest was 100 mL. Overall, there was an increase in daily ascitic fluid volume extraction after day 7. However, correlations between volume extraction and changes in GFR or hormones were not statistically significant. It should be noted that in those patients who developed AKI or any other adverse event, ascitic fluid volume removal was reduced until the adverse event had resolved. Although 4 out of the 10 (40%) patients did not require more LVP after alfapump implant, the remaining 6 (60%) patients required LVP during follow-up. Overall there was a mean requirement of 7.5 LVP per patient during the previous 3 months before study inclusion. After alfapump implantation, mean LVP requirement in 3-month intervals was significantly reduced to 1.8, 3.7, 3.2, and 2.4 at 0-3, 3-6, 6-9, and 9-12 months follow-up periods. The main reasons for LVP requirements were technical problems precluding the correct functioning of the device (see below) or cirrhosis-related adverse events that did not allow an adequate increase in the volume of ascites removed. It should be noted that among all the paracentesis performed, in only 3 patients the paracentesis was performed 5 days before the study control visit, were hormones, and GFR was measured. However, we do not consider that paracentesis could have influenced the results because the volume of ascites removed in these patients was relatively low (4.5, 5, and 3 L, respectively) and in all cases patients received volume expansion with intravenous albumin.
Finally, only 4 out of the 10 (40%) patients received diuretic treatment during the study period, which was indicated for the management of edema. In all cases, treatment was effective, and the dose of diuretic used was relatively low: all patients received spironolactone 50 mg/day 6 furosemide 40 mg/day, and only 1 patient received spironolactone 100 mg/day. Results considering changes in GFR and endogenous vasoconstrictor systems were similar in patients receiving diuretic treatment compared with those patients who did not receive diuretics.
ADVERSE EVENTS
Adverse events recorded during the 12-month followup study period were categorized into 2 groups:
1. Adverse events related to complications of cirrhosis. 2. Adverse events related to the implantation procedure and/or the alfapump system itself.
Cirrhosis-Related Adverse Events
Overall, there were 68 episodes of cirrhosis-related adverse events in 8 patients during the study period (average of 9 complications per patient; Table 3 ). Two patients did not develop complications. The common characteristic of these 2 patients is that both had low MELD scores (8 and 10, respectively), compared with patients who developed complications who had a median MELD score of 12 (range, 9-21). The most frequent complication was AKI with 18 episodes in 7 patients, followed by bacterial infections (17 episodes in 6 patients). Table 4 summarizes the characteristics of AKI episodes during the study period. Only 4 out of the 18 episodes occurred within the first 7 days after the alfapump was implanted, whereas the remaining 14 episodes developed during follow-up. Most episodes were AKI stage 1 (n 5 14; 78%). The etiology of AKI was hypovolemic in 3 patients, nephrotoxicity associated with the administration of NSAIDs in 2 patients, hepatorenal syndrome associated with bacterial infections in 3 patients, acute tubular necrosis (ATN) in 1 patient, and urinary peritonitis due to bladder perforation in another patient. In the 2 patients with nephrotoxicity, NSAIDs were administered in other hospitals and patients were referred to our center once AKI had developed. It should be noted that in 8 (44%) episodes, no precipitating factor of AKI could be identified. All these episodes were AKI stage 1, and patients were managed with either no specific treatment or reduction in daily ascitic fluid volume removal by the alfapump system with resolution of AKI in all cases.
CHARACTERISTICS OF AKI EPISODES
Finally, it should be noted that there were no significant differences in the development of episodes of AKI in patients divided according to the administration of diuretic treatment.
CHARACTERISTICS OF BACTERIAL INFECTIONS
Characteristics of bacterial infections are described in Table 3 . Overall, there were 17 episodes in 6 patients, leading to hospital admission with long hospital stays. In total, the length of hospital stay secondary to bacterial infections was 287 days (range, 41-104 days) which represents 47.8 days/patient. The most common type of bacterial infection was urinary tract infection with 8 episodes occurring in 5 patients. The second most frequent type of infection was ascitic fluid infection. One patient presented persistent ascitic fluid colonization by Candida glabrata that required 1-month antifungal treatment. The infection resolved without the need to remove the alfapump system. Two other patients developed persistent bacterial peritonitis by Pseudomona aeruginosa. One of these patients developed ascitic fluid leakage to the subcutaneous pocket around the pump 4 months after surgery, which was finally associated with skin infection and ascitic fluid infection. In both patients, the alfapump system had to be removed due to persistent ascitic fluid infection that could not be resolved with antibiotic therapy. Table 5 describes the type and number of adverse events related to the procedure and the device. Overall, there were 15 device-or procedure-related adverse events in 7 patients, which resulted in 6 surgical reinterventions. There were 2 episodes of migration of the peritoneal catheter to the perihepatic area resulting in impaired ascites mobilization. In 1 patient, the peritoneal catheter was relocated by laparoscopy. In the other patient, no procedure was performed due to significant comorbidities and advanced liver disease with high surgical risk. In 2 other patients, the peritoneal catheter had to be replaced, in 1 patient due to obstruction and in the other due to persistent ascitic fluid infection. Finally, in 3 patients the alfapump system had to be replaced or removed, in 2 patients due to persistent ascitic fluid infection and in 1 patient due to device dysfunction.
DEVICE AND PROCEDURE-RELATED ADVERSE EVENTS
One patient presented a urinary bladder leakage that was diagnosed by a computed tomography scan performed 3 days after implantation surgery due to persistent abdominal pain together with increased creatinine levels in ascitic fluid. The patient was managed with conservative treatment which consisted of the placement of a urinary bladder catheter during 4 weeks, with complete resolution of the bladder leakage.
Finally, there were a few technical problems. There were problems in the device charging in 1 patient that were solved by modifying the charging pattern (charging the device 10 minutes 3 times a day instead of 30 minutes once a day). Two patients experienced transient device dysfunction that was manifested by ascitic fluid accumulation and was solved by changing the device settings. Finally, 1 charger failed and had to be substituted.
MORTALITY AND LONGTERM FOLLOW-UP
Five patients died within the 12-month follow-up period. Causes of death were acute-on-chronic liver failure (ACLF) in 3 patients, refractory gastrointestinal bleeding in another patient, and liver failure in 1 patient. Another patient died 4 months after the end of the study due to ACLF associated with sepsis.
As described above, in 1 patient, the alfapump system did not work from month 5 after implantation due to peritoneal catheter migration. Therefore, data on longterm follow-up (1 year) with the alfapump system working properly was only available in 3 patients. It should be noted that in all 3 of these patients, the alfapump system stopped working between 2 and 3 years after implantation, a time period which corresponds to the lifetime of the system as indicated by the company. In 2 out of these 3 latter patients, there were adverse events occurring during the longterm followup period. One patient developed a subcutaneous abscess in the hypogastric area in relation to the bladder catheter, and another patient presented hypogastric pain and hematuria due to catheter friction with the bladder wall. In both patients, the alfapump system was removed. The third patient, in whom the alfapump system stopped working, is currently scheduled to have the system removed.
Discussion
The main result of the current study is that there was a progressive and significant decrease in GFR after implantation of the alfapump system. In addition, circulatory function was investigated in detail. Although there were no significant changes in mean arterial pressure or cardiac output, there was a significant and marked activation of endogenous vasoconstrictor systems, as assessed by changes in PRA and norepinephrine concentration, from the first month and during study follow-up. A large body of evidence indicates that the activity of the renin-angiotensin system and sympathetic nervous system are very sensitive markers of circulatory function in cirrhosis. (15) (16) (17) (18) Therefore, these results suggest that patients developed an impairment of effective arterial blood volume throughout the study period. The absence of a statistically significant correlation between changes in GFR and changes in PRA and norepinephrine concentration does not rule out a role for the changes in vasoconstrictor systems in the impairment of kidney function, because other systems may act by counterbalancing the effects of vasoconstrictors on the renal circulation, such as prostaglandins, that were not measured in this study. Therefore, the observation of a chronological relationship between the 2 phenomena (decrease in GFR and increase in hormones) suggests a cause-effect relationship.
These findings mimic the effects reported in patients undergoing LVP without albumin administration or in patients with spontaneous bacterial peritonitis not receiving albumin. (6, (19) (20) (21) (22) It is important to remark that impairment in effective arterial blood volume in cirrhosis is associated with increased risk of kidney impairment and poor prognosis. (19, 20) Moreover, the absence of changes in cytokine levels during follow-up rules out an increase in inflammatory response and, therefore, further supports the hypothesis that the impairment of circulatory function played a key role in the pathogenesis of kidney impairment in this setting.
Besides kidney and circulatory function, adverse events were also analyzed during the study follow-up period. First, it should be mentioned that the surgical procedure could be performed in all patients without complications, in a mean time of 55 minutes. To avoid adverse events, the alfapump system was kept inactive during the first 24 hours after surgery. This did not have any impact in the subsequent correct operation of the device. Overall, although subjects included in the study were patients with refractory ascites who are prone to develop complications, the number of adverse events occurring during the study appears to be too high, particularly considering that this was a very selected group of patients with refractory ascites, with preserved liver function (most of them were Child B and average MELD score was only 11). Considering the adverse events related to complications of cirrhosis, it should be noted that the most common complication was AKI. Although most episodes were AKI stage 1 and in most patients AKI was reversible, patients developed up to 18 episodes of AKI during the study period. Aside from a few cases related to infections, nephrotoxicity, or ATN, in most cases the cause of AKI was either related to hypovolemia or could not be identified. In these cases, AKI was solved after rehydration together with reducing the total ascitic fluid volume removed by the alfapump system. Although there was no control group, considering the labile kidney function existing in patients with advanced cirrhosis and the occurrence of several episodes of AKI following alfapump implantation, it could be hypothesized that AKI episodes could be explained by the effective hypovolemia induced by continuous ascitic fluid removal by the alfapump system. The other most frequent complications of cirrhosis after AKI were bacterial infections, particularly urinary tract infections and ascitic fluid infection, followed by hepatic encephalopathy, and hyponatremia.
Currently, information on the safety of the alfapump system is very limited and almost all available data come from the PIONEER study. (9) Our results are in keeping with those observed in this study, in which bacterial infections, hepatic encephalopathy, and AKI were also the most common cirrhosis-related adverse events with 40, 17, and 13 episodes, respectively, in 40 patients. In a recent study that reports a single-center experience with 10 patients who were treated with the alfapump system, prerenal AKI was also reported as a common complication. (23) The frequency of device-related adverse events was also relatively high in our series, leading to device dysfunction in some cases and requiring 6 surgical reinterventions, which represents a high-risk procedure in patients with refractory ascites.
Overall, the rationale for the alfapump device performance could remind that of another classical treatment approach for refractory ascites, the peritoneovenous shunt (LeVeen shunt). Both devices are aimed at moving ascitic fluid from the peritoneal cavity to other compartments. The alfapump system moves ascites to the urinary bladder where it can be eliminated through normal urination, instead of returning ascites to the vascular compartment, the approach used by the peritoneovenous shunt. (24) However, some of the adverse events described in this study are reminiscent of those occurring with the peritoneovenous shunts, such as bacterial infections and device obstruction. (25) The present study has some limitations that should be acknowledged. First, the sample size is small and therefore conclusions should be taken with caution. Moreover, there was no control group because this was designed as a proof-of-concept study. However, despite these limitations, patients included were studied very carefully and the main variables of the study, kidney and circulatory function, are objective parameters that were evaluated using "state-of-the-art" techniques. In this context, with the results of the present study we would like to raise a note of caution about the use of the alfapump system in patients with cirrhosis and refractory ascites. While waiting for the results of future studies, it should be noted that a close monitoring of fluid balance, including body weight and kidney function, should be performed in these patients to prevent adverse events. Moreover, these results support the rationale to think that concomitant administration of intravenous albumin during alfapump therapy could be useful to avoid kidney impairment and suppress the activation of vasoconstrictor systems. Finally, although results should be taken with caution due to the low sample size, it appears that those patients with lower MELD scores were those doing better and showing fewer adverse events.
In conclusion, the results of the present study show that patients with cirrhosis and refractory ascites treated with the alfapump system develop a decrease in GFR together with a marked activation of endogenous vasoconstrictor systems. Moreover, the number of adverse events, particularly AKI and infections and devicerelated adverse events was high. The close chronological relationship observed between kidney impairment and vasoconstrictor systems activation and the alfapump system implant suggests a cause-effect relationship. Therefore, these findings raise the possibility that continuous removal of ascites, even in low amounts, without albumin administration, may induce a further impairment of effective hypovolemia characteristic of patients with refractory ascites, mimicking a PPCD syndrome. This possible cause-effect relationship should ideally be confirmed in larger series of patients. Moreover, considering the results of this study, the potential effectiveness of intermittent administration of albumin in counteracting these effects should be investigated in future studies.
